Health Canada approves MedMira’s Reveal® Rapid TP Test – Urgent New Tool In The Battle Against Syphilis

Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada. A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in […]
Corporate Update on Clinical Evaluation of MedMira’s Products

Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended […]
Update on MedMira’s Reveal® TP (Syphilis) Clinical Trials in Canada

Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test. The Company has successfully started its clinical trials in Saskatchewan in early March 2023 and commences another trial in British Colombia by the […]